Thermo Fisher Sells Microbiology Unit to Astorg for $1.075 Billion — Thermo Fisher Scientific Inc.

Event summary

Thermo Fisher Scientific completed the sale of its microbiology business to private equity firm Astorg for $1.075 billion, including a $50 million seller note.
The divested unit generated $645 million in revenue in 2025 and was part of Thermo Fisher's Specialty Diagnostics segment.
Astorg is a leading pan-European private equity firm specializing in healthcare investments.

The big picture

Thermo Fisher's divestiture reflects a broader trend of life sciences companies streamlining portfolios to focus on core high-growth segments. The $1.075 billion sale to Astorg highlights private equity's appetite for specialized diagnostics assets amid increasing demand for antimicrobial testing solutions. With annual revenue exceeding $45 billion, Thermo Fisher is positioning itself to prioritize higher-margin areas while Astorg aims to unlock value in the microbiology business.

What we're watching

Portfolio Focus: How Thermo Fisher will allocate resources from the $1.075 billion divestiture proceeds to accelerate growth in higher-margin segments.
Private Equity Strategy: Whether Astorg can drive operational improvements and expand the microbiology business's market share post-acquisition.
Regulatory Dynamics: The pace at which regulatory changes in clinical diagnostics may impact the acquired unit's growth trajectory under new ownership.